Literature DB >> 11029402

Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction.

C Fernandez-Patron1, K G Stewart, Y Zhang, E Koivunen, M W Radomski, S T Davidge.   

Abstract

Matrix metalloproteinase (MMP)-2 has been historically associated with the process of vascular remodeling through the cleavage of extracellular matrix proteins. However, we recently found that MMP-2 also cleaves the endothelium-derived peptide big endothelin-1, ET-1[1-38] and yields the novel vasoconstrictor ET-1[1-32]. We therefore investigated the effects of MMP-2 inhibitors as potential vasodilators. MMP inhibition with ortho-phenanthroline (0.3 to 30 micromol/L) induced vasorelaxation of isolated rat mesenteric arteries (maximum of relaxation=74.5+/-27.6% at 30 micromol/L). However, phosphoramidon (0.3 to 30 micromol/L), which inhibits some metalloenzymes, but not MMP-2, did not dilate the arteries. Selective inhibition of endogenous MMP-2 with the novel tissue-permeable cyclic peptide CTTHWGFTLC (CTT, 10 micromol/L) also caused vasorelaxation (by 85+/-6%), whereas STTHWGFTLS (10 micromol/L), an inactive CTT analogue, did not dilate the arteries. Interestingly, the vasorelaxation that results from MMP-2 inhibition was endothelium-independent. Thus, we examined whether MMP-2 acted on peptides derived from the smooth muscle or the perivascular nerves. Recombinant human MMP-2 cleaved calcitonin gene-related peptide (CGRP) specifically at the Gly(14)-Leu(15) peptide bond and reduced the vasodilatory potency of CGRP by 20-fold. Inhibition of MMP-2 increased the amount of intact CGRP in arteries and enhanced vasorelaxation induced by anandamide, which stimulates CGRP release. Vasorelaxation in response to MMP-2 inhibition was abolished by CGRP[8-37], a selective CGRP receptor antagonist, and by capsaicin, which depletes arterial perivascular nerves of CGRP. We conclude that vascular MMP-2 cleaves endogenous CGRP and promotes vasoconstriction. These data suggest a novel mechanism of regulating the vasoactive and, possibly, the neurohormonal actions of CGRP and establish MMP-2 as a modulator of vascular function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11029402     DOI: 10.1161/01.res.87.8.670

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  39 in total

1.  Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets.

Authors:  Anna Radomski; Paul Jurasz; Esmond J Sanders; Christopher M Overall; Heather F Bigg; Dylan R Edwards; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension.

Authors:  C S Ceron; M M Castro; E Rizzi; M F Montenegro; V Fontana; M C O Salgado; R F Gerlach; J E Tanus-Santos
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

3.  Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction.

Authors:  Jiqiu Chen; Ching-Hsuan Tung; Jennifer R Allport; Si Chen; Ralph Weissleder; Paul L Huang
Journal:  Circulation       Date:  2005-04-04       Impact factor: 29.690

Review 4.  Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis.

Authors:  Mingyi Wang; Soo Hyuk Kim; Robert E Monticone; Edward G Lakatta
Journal:  Hypertension       Date:  2015-02-09       Impact factor: 10.190

5.  Constriction of carotid arteries by urokinase-type plasminogen activator requires catalytic activity and is independent of NH(2)-terminal domains.

Authors:  Philip G Massey; Shinji Tanaka; Joshua M Buckler; Bo Jiang; Anton McCourtie; Kun Qian; Clifford Tom; April Stempien-Otero; Shan Wen; Ian Luttrell; Kanchan Chitaley; David A Dichek
Journal:  Thromb Haemost       Date:  2009-11       Impact factor: 5.249

6.  Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats.

Authors:  Stephen F Rodrigues; Edward D Tran; Zuleica B Fortes; Geert W Schmid-Schönbein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

Review 7.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

8.  Selenium restores defective beta-adrenergic receptor response of thoracic aorta in diabetic rats.

Authors:  Esma N Zeydanli; Ayca Bilginoglu; Evrim Tanriverdi; Hakan Gurdal; Belma Turan
Journal:  Mol Cell Biochem       Date:  2009-12-18       Impact factor: 3.396

9.  Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth.

Authors:  Marten Falkenberg; Clifford Tom; Mary Beth DeYoung; Shan Wen; Ruth Linnemann; David A Dichek
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

Review 10.  Matrix metalloproteinases as drug targets in preeclampsia.

Authors:  Ana C T Palei; Joey P Granger; Jose E Tanus-Santos
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.